



Scientific Chair:
Nathalie Albert, Munich

Scientific Co-Chair:
Matthias Preusser, Vienna

Scientific Committee:
Martin van den Bent, Rotterdam
Michael Weller, Zurich
Jolanta Kunikowska, Warsaw
Emilie Le Rhun, Zurich
Norbert Galldiks, Cologne
Marcus Hacker, Vienna
Giuseppe Minniti, Rome
Karl Rössler, Vienna
Nelleke Tolboom, Utrecht
Francesco Cicone, Catanzaro
Anna Berghoff, Vienna



**DIAGNOSTIC AND THERAPEUTIC INNOVATIONS
IN THE ERA OF PRECISION MEDICINE –
NUCLEAR MEDICINE MEETS NEURO-ONCOLOGY**

POCKET PROGRAM

NMN Symposium: Precision Medicine

26.-27. April 2024 / Vienna, Austria
Billrothhaus, Gesellschaft der Ärzte

www.nmn-society.org

Nuclear Medicine and Neurooncology (NMN)



Fight your cancer within the **MINUTE**

MOLECULAR INTERNAL NUCLIDE THERAPY



2	PRESIDENTIAL ADDRESS
3	BOARD - SCIENTIFIC COMMITTEE – ORGANISATION
4	PROGRAM OVERVIEW
4	FRIDAY, 26. APRIL 2024
6	SATURDAY, 27. APRIL 2024
9	POSTER INFORMATION
15	SPONSORS
16	GENERAL INFORMATION
18	NETWORKING EVENT
19	FUTURE NMN SYMPOSIUM
20	FLOOR PLAN

PRESIDENTIAL ADDRESS

Dear colleagues,

We are delighted to welcome you in Vienna for the first “**Diagnostic and Therapeutic Innovations in the Era of Precision Medicine – Nuclear Medicine Meets Neuro-Oncology (NMN)**” Symposium taking place from **April 26th - 27th, 2024**.

With this symposium we aim to provide a prime platform for networking and discussion of the most novel data in the field of molecular imaging and theranostics in Neuro-Oncology. The program of the symposium will highlight the most recent findings in basic, translational, and clinical science in this exciting and evolving field of research. We are very proud and grateful for the outstanding speaker panel and faculty with top speakers from all over the world and from different specialties! Furthermore, we are very happy to have received 42 high quality submissions of original contributions that will be shared in oral and poster presentations and will surely lead to lively exchange and generate new cooperations and research ideas.

We thank the NMN Meeting Office, the Scientific Committee, and all supporters for the hard work and fantastic collaboration in organizing the symposium! Let's enjoy together the exciting scientific exchange during the main symposium program, as well as the strengthening of collaborations and friendships during our networking activities!

Welcome to Vienna - we are very excited about so many bright brains coming together for the NMN Symposium 2024!

Nathalie L. Albert
Scientific Chair

Matthias Preusser
Scientific Co-Chair

NMN Board


Matthias Preusser, Vienna, Chairperson
Nathalie L. Albert, Munich, Secretary

NMN Scientific Committee

Nathalie L. Albert, Munich, Scientific Chair
Matthias Preusser, Vienna, Scientific Co-Chair
Martin van den Bent, Rotterdam
Michael Weller, Zurich
Jolanta Kunikowska, Warsaw
Emilie Le Rhun, Zurich
Norbert Galldik, Cologne
Marcus Hacker, Vienna
Giuseppe Minniti, Rome
Karl Rössler, Vienna
Nelleke Tolboom, Utrecht
Francesco Cicone, Catanzaro
Anna Berghoff, Vienna

NMN Symposium Organizer

Nuclear Medicine and Neurooncology c/o WMA GmbH
Alser Strasse 4
1090 Vienna, Austria



Scientific Management, Exhibition, Sponsorship, General Organization and Logistics

WMA GmbH
Christine Voß
Lydia Schnedl
T: +43 1 405 13 83 – 37
E: nmn@wma.co.at
W: www.nmn-society.org



PROGRAM OVERVIEW

Friday, 26. April 2024

All times refer to Central European Summer Time (CEST).

09:45 – 10:00 Welcome and Introduction

- Nuclear Medicine meets Neuro-Oncology
– Nathalie L. Albert (Munich), Matthias Preusser (Vienna)

10:00 – 12:00 Theranostic treatments: current state and future prospects

Chairs: Christophe Deroose (Leuven), Anna Berghoff (Vienna)

- Molecular targets for theranostic treatments of CNS tumors
– Jolanta Kunikowska (Warsaw), 15+15'
- Radioligand therapies for gliomas: emerging trial landscape
– Michael Weller (Zurich), 15+15'
- Radioligand therapies for meningioma: emerging trial landscape
– Nathalie L. Albert (Munich), 15+15'
- Theranostics for CNS metastases: overlooked potential?
– Matthias Preusser (Vienna), 15+15'

12:00 – 13:00 Lunch Break

13:00 – 14:30 Proffered papers: Hot Data and Burning Questions

Chairs: Roberta Rudà (Turin), Tatjana Traub-Weidinger (Vienna)

- Hotspot: Clinical Trials
 - ◇ Role of FET-PET-based re-irradiation in recurrent glioblastoma – results of a prospective randomized clinical trial – Anca Grosu (Freiburg), 7+3', [Abstract no. 35](#), [Poster no. P01](#)
 - ◇ Rhenium (186Re) Obisbameda (Rhenium-186 Nanoliposome, 186RNL) trial updates: ReSPECT-LM Phase 1, ReSPECT-GBM Phase 1/2, and ReSPECT-GBM Phase 2 – Andrew Brenner (San Antonio), 7+3', [Abstract no. 16, 22, 23](#), [Poster no. P02, P03, P04](#)
 - ◇ Multi-site, prospective trial evaluating FET-PET In Glioblastoma (FIG) Study (TROG 18.06): Central review of initial FET-PET biologic target volume delineation for radiation planning – Eng-Siew Koh (Sydney), 7+3', [Abstract no. 13](#), [Poster no. P05](#)
 - ◇ 11C-Methionin PET for radiotherapy treatment planning in patients with rapid early progression after glioblastoma surgery: prospective phase II trial – Tomas Kazda (Brno), 3+2', [Abstract no. 28](#), [Poster no. P06](#)
 - ◇ Feasibility and tolerability of [¹³¹I]I-PA monotherapy in progressive and recurrent high grade gliomas; a single institution case series – Nelleke Tolboom (Utrecht), 3+2', [Abstract no. 25](#), [Poster no. P07](#)
- Hotspot: PET Imaging
 - ◇ Assessment of FET PET-based response in patients with gliomas using the PET RANO 1.0 criteria – Norbert Galldiks (Cologne), 3+2', [Abstract no. 17](#), [Poster no. P08](#)
 - ◇ Measurable disease for response assessment in IDH-wildtype glioblastoma – a comparison of MRI-based (RANO 2.0) versus PET-based (PET RANO 1.0) assessment – Katharina Müller (Munich), 3+2', [Abstract no. 20](#), [Poster no. P09](#)

Friday, 26. April 2024

- ◇ Prognostic value of [18F]-FET-PET in diffuse low-grade glioma (Grade 2 WHO CNS 2021) – Michael Mütter (Münster), 3+2', [Abstract no. 30](#), [Poster no. P10](#)
- ◇ Evaluation of the Utility of PET Imaging Based on WHO Classification 5th edition for Brain Tumor Diagnosis – Keisuke Miyake (Kagawa), 3+2', [Abstract no. 14](#), [Poster no. P11](#)
- ◇ Development of [18F]AG-120 as radiotracer for the detection by positron emission tomography (PET) of the mutant isocitrate dehydrogenase 1 in glioma – Magali Toussaint (Leipzig), 3+2', [Abstract no. 12](#), [Poster no. P12](#)
- ◇ Translating immunoPET imaging of PD-L1 in glioblastoma: journey from the laboratory to clinical practice – Gabriela Kramer-Marek (Sutton), 3+2', [Abstract no. 40](#), [Poster no. 13](#)
- **Hotspot: Theranostics**
 - ◇ Promising theranostic targets for high-grade pediatric central nervous system tumors – Sabine Plasschaert (Utrecht), 3+2', [Abstract no. 9](#), [Poster no. P14](#)
 - ◇ Exploring theranostic potential: FAP expression in brain metastases and novel FAPI radiotracers with an alpha-ketoamide warhead – Petr Vymola (Prague), 3+2', [Abstract no. 18](#), [Poster no. P15](#)
 - ◇ Fibroblast activating protein (FAP) expression as potential theranostics target in high-grade meningioma – Maximilian Mair (Vienna), 3+2', [Abstract no. 39](#), [Poster no. P16](#)
 - ◇ Investigating the radiobiological response to PRRT using patient-derived meningioma spheroids – Eleke Bos (Rotterdam), 3+2', [Abstract no. 29](#), [Poster no. P17](#)

14:30 – 15:00 Coffee Break

15:00 – 17:00 Clinical trial conduct: challenges and opportunities

Chairs: Evanthia Galanis (Rochester), Emilie Le Rhun (Zurich)

- Investigator perspective (Clinical Neuro-Oncologist)
– Martin van den Bent (Rotterdam), 15+15'
- Investigator perspective (Nuclear Medicine Physician)
– Wim Oyen (Milan/Arnhem), 15+15'
- Industry perspective
– Daniela Niepel (Novartis), 15+15'
- Panel discussion, 30'

17:00 – 18:00 Poster viewing – Drinks and Science

19:00 Networking Evening at the City Hall of Vienna

For further information see page 18

PROGRAM OVERVIEW

Saturday, 27. April 2024

09.00-10.00 Meet the Editor Session – Ulrike Harjes (Nature Medicine)

Pre-registration required in order to participate.

10.00-12.00 PET Imaging for Improved Patient Management

Chairs: Ingo Mellinghoff (New York), Karl Rössler (Vienna)

- PET for neurosurgery: nice to have or must have?
– Jörg-Christian Tonn (Munich), 15+15'
- PET for radiotherapy of CNS tumors: where is the evidence?
– Giuseppe Minniti (Rome), 15+15'
- PET for IDH inhibitor therapy: helpful for patient selection and monitoring?
– Timothy Cloughesy (Los Angeles), 15+15'
- What should be visualized? A clinician's wish list
– Norbert Galldiks (Cologne), 15+15'


12.00-13.00 Lunch Break

13.00-14.30 PET Imaging: Future prospects

Chairs: Benjamin Ellingson (Los Angeles), Michael Lim (Stanford)

- RANO 2.0 criteria for MRI-based response assessment of gliomas
– Patrick Wen (Boston), 15'+15'
- PET RANO criteria for response assessment of gliomas
– Nathalie L. Albert (Munich), 15+15'
- Do we need PET for CNS lymphomas?
– Marius Mayerhoefer (New York), 15+15'

14.30-15.00 Coffee Break



Saturday, 27. April 2024

15.00-17.00 Radiopharmacology: understanding the basics

Chairs: Erik Sulman (New York), Marcus Hacker (Vienna)

- **Tracer development for theranostics: how to construct a magic bullet**
– Clemens Kratochwil (Heidelberg), 15+15'
- **Optimizing radioligand therapy delivery to CNS tumors: role of the blood-brain/blood tumor barrier**
– Nelleke Tolboom (Utrecht), 15+15'
- **Do we need dosimetry for optimization of theranostics in CNS tumors?**
– Francesco Cicone (Catanzaro), 15+15'
- **Panel discussion, 30'**

17:00 Conclusion and Farewell

Nathalie L. Albert (Munich), Matthias Preusser (Vienna)

All contents are as per date of printing (16. April 2024).


The up-to-date scientific program is available in the online program on the symposium website.

The organizer reserves the right to modify the program in case of external or unforeseen circumstances and cannot assume any liability. No refunds can be granted in case of cancellations of speakers, lack of space in the lecture room or any other incidents during the symposium which are beyond the control of the organizer.



Leading the Science to Advance the Development of Targeted Antibody Drug Conjugates for More Patients Around the World

We are leveraging
each other's
strengths in
oncology to treat
cancers with high
unmet need



Posters will be on display on Friday, April 26, 2024 from 08.30-18.00h in the Verwaltungszimmer/Council Room on the 1st floor as well as the Seminarraum/Seminar Room and Große Bibliothek/Grand Library on the ground floor.

A dedicated **poster viewing session** is scheduled on **Friday, April 26, 2024 from 17.00-18.00h**. To enable discussion and interaction poster presenters or one of their group members are asked to be present at the poster board during this time.

A list of posters presented can be found from page 10 onwards.
Poster numbers will be shown on the poster boards.

Poster mounting and removal

Registration and poster mounting will be open from 08.30 on Friday morning, April 26, 2024. **All posters must be removed after the poster presentation on Friday, April 26, 2024, until 18.15h.** Posters that have not been removed will be taken down and will not be stored or sent to the authors afterwards.


Only adhesive tape can be used to mount posters. Material will be available onsite.

Poster Topics

1. Brain Metastasis
2. Glioma
3. Lymphoma
4. Meningioma
5. Other

Abstracts

Abstracts presented at the **NMN Symposium 2024** are available on the symposium website.



POSTER INFORMATION

Poster List


Poster Nr.	Titel	First Name	Last Name	Country
Verwaltungsratszimmer/Council Room				1st Floor
P01	Role of FET-PET-based re-irradiation in recurrent glioblastoma - results of a prospective randomized clinical trial	Anca	Grosu	Germany
P02	ReSPECT-LM Phase 1 Dose Escalation Trial of Rhenium (186Re) Obisbameda (Rhenium-186 Nanoliposome, 186RNL) in Leptomeningeal Metastases (LM)	Andrew	Brenner	United States
P03	Update Report of the ReSPECT-GBM Phase 1/2 Dose Escalation Trial of Rhenium (186Re) Obisbameda (Rhenium-186 Nanoliposome, 186RNL) in Recurrent Glioma via Convection Enhanced Delivery (CED)	Andrew	Brenner	United States
P04	Rhenium (186Re) Obisbameda (Rhenium-186 Nanoliposome, 186RNL) in Recurrent Glioblastoma (rGBM) via Convection Enhanced Delivery (CED): ReSPECT-GBM Phase 2 Trial Update	Andrew	Brenner	United States
P05	Multi-site, prospective trial evaluating FET-PET In Glioblastoma (FIG) Study (TROG 18.06): Central review of initial FET-PET biologic target volume delineation for radiation planning.	Eng-Siew	Koh	Australia
P06	11C-Methionin PET for radiotherapy treatment planning in patients with rapid early progression after glioblastoma surgery: prospective phase II trial	Tomas	Kazda	Czech Republic
P07	Feasibility and tolerability of [¹³¹ I]-PA monotherapy in progressive and recurrent high grade gliomas; a single institution case series.	Nelleke	Tolboom	Netherlands
P08	Assessment of FET PET-based response in patients with gliomas using the PET RANO 1.0 criteria	Norbert	Galldiks	Germany
P09	Measurable disease for response assessment in IDH-wildtype glioblastoma- a comparison of MRI-based (RANO 2.0) versus PET-based (PET RANO 1.0) assessment	Katharina	Müller	Germany

P10	Prognostic value of [18F]-FET-PET in diffuse low-grade glioma (Grade 2 WHO CNS 2021)	Michael	Müther	<i>Germany</i>
P11	Evaluation of the Utility of PET Imaging Based on WHO Classification 5th edition for Brain Tumor Diagnosis	Keisuke	Miyake	<i>Japan</i>
P12	Development of [18F]AG-120 as radiotracer for the detection by positron emission tomography (PET) of the mutant isocitrate dehydrogenase 1 in glioma	Magali	Toussaint	<i>Germany</i>
P13	Translating immunoPET imaging of PD-L1 in glioblastoma: journey from the laboratory to clinical practice	Gabriela	Kramer-Marek	<i>United Kingdom</i>
P14	Promising theranostic targets for high-grade pediatric central nervous system tumors	Sabine	Plasschaert	<i>Netherlands</i>
P15	Exploring theranostic potential: FAP expression in brain metastases and novel FAPI radiotracers with an alpha-ketoamide warhead	Petr	Vymola	<i>Czech Republic</i>
P16	Fibroblast activating protein (FAP) expression as potential theranostics target in high-grade meningioma	Maximilian	Mair	<i>Austria</i>
P17	Investigating the radiobiological response to PRRT using patient-derived meningioma spheroids	Eelke	Bos	<i>Netherlands</i>
P18	Correlations of 18F-DOPA PET metrics with the Ki-67 proliferation labeling index in gliomas	Deanna	Pafundi	<i>United States</i>
P19	68Ga/177Lu-PSMA theranostics in recurrent high-grade glioma - first study results	Anna	Karlberg	<i>Norway</i>
Seminarraum/Seminar Room			Ground Floor	
P20	Differential gradients in neoplastic and inflammatory cell populations within peritumoural regions in high grade glioma a dual PET tracer and MRI study	Bandar	Alfaifi	<i>United Kingdom</i>
P21	FET PET uptake characteristics in IDH-mutant glioma	Enio	Barci	<i>Germany</i>
P22	Radiomic analysis of conventional MRI for the prediction of F-DOPA PET uptake characteristics in patients with brain metastases following stereotactic radiosurgery	Francesco	Cicone	<i>Italy</i>

POSTER INFORMATION

P23	Hybrid [18F]FET PET-MRI; a valuable advanced imaging tool to discriminate between progression of disease and treatment-related changes in glioma patients	Jessica	de Jong	<i>Netherlands</i>
P24	68Ga-DOTATATE PET-CT in treatment planning of robotic stereotactic CyberKnife radiation therapy in patients with intracranial meningiomas	Hanna	Grzbiela	<i>Poland</i>
P25	PET probe development for the Sigma2 receptor imaging in brain tumours - Preclinical evaluation of [18F]RM273	Daniel	Guendel	<i>Germany</i>
P26	Safety of lutetium Lu 177 dotatate for recurrent meningioma with history of radiation necrosis - a case report	Derek	Johnson	<i>United States</i>
P27	Response of untreated meningioma to Lu-177 DOTATATE: case report and call for further study	Derek	Johnson	<i>United States</i>
P28	Background region selection in FDOPA PET - comparison of two methods	Derek	Johnson	<i>United States</i>
P29	Physiologic FDOPA uptake in the basal ganglia - implications for tumor delineation in patients with newly diagnosed glioblastoma	Derek	Johnson	<i>United States</i>
P30	Survival prediction for glioma patients at initial diagnosis using multimodal radiomics	Lena	Kaiser	<i>Germany</i>
P31	Fostering clinical translation of artificial intelligence in neuro-oncology - establishing an infrastructure for multi-centric data collection, exchange, and analysis	Philipp	Lohmann	<i>Germany</i>
P32	Predicting intraoperative 5-ALA fluorescence in diffuse low-grade gliomas using preoperative FET-PET	Michael	Müther	<i>Germany</i>
P33	Fractionated intracavitary radioimmunotherapy with Lu-177 labeled 6A10 Fab fragments in patients with malignant glioma: a phase I trial to determine maximum tolerated dose and toxicity	Michael	Müther	<i>Germany</i>
P34	Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga] Ga-DOTATOC PET in patients with meningioma	Martha	Nowosielski	<i>Austria</i>
P35	Impact of FET-PET imaging in surveillance of theranostic treatment with 4-L-[131I] iodo-phenylalanine ([131I]IPA) in relapsed glioblastoma patients	Josef	Pichler	<i>Austria</i>

Große Bibliothek/Grand Library		Ground Floor		
P36	FET-PET-Guided management of pseudoprogression in glioblastoma (the FET POPPING trial): protocol for a diagnostic randomized clinical trial	Veerle	Ruijters	<i>Netherlands</i>
P37	¹⁷⁷ Lu-PSMA radioligand therapy in patients with brain metastases from prostate cancer: the Innsbruck experience.	Giulia	Santo	<i>Austria</i>
P38	CITADEL-123. TRIAL IN PROGRESS A Phase I clinical trial to assess the activity of I-123 Poly Adenosine Diphosphate Ribose Polymerase I inhibitor (123I-ATT001) directly administered in subjects with relapsed glioblastoma.	Austin	Smith	<i>Germany</i>
P39	Analysis of tumor relapse probability and overall survival prediction following concomitant radiotherapy with temozolomide using FET PET in patients with glioblastoma	Isabelle	Stetter	<i>Germany</i>
P40	Amino-acid PET as an adjunct to conventional MRI improves the diagnosis of aggressive glial lesions	Antoine	Verger	<i>France</i>
P41	Assessment of response to lomustine-temozolomide chemotherapy in addition to radiotherapy in patients with newly diagnosed glioblastoma using FET PET	Jan-Michael	Werner	<i>Germany</i>
P42	Application of the PET RANO 1.0 criteria in diffuse glioma: retrospective single center experience	Lilian	Wiegand	<i>Germany</i>





We thank our valued partners for their support.

PLATINUM SPONSOR



GOLD SPONSORS



SILVER SPONSORS



GENERAL SPONSORS



TRAVEL SCHOLARSHIP



GENERAL INFORMATION

Registration Opening Hours

Friday, April 26, 2024: 08:30 – 18:00 hrs
Saturday, April 27, 2024: 08:30 – 17:00 hrs



Location and Accessibility

Billrothhaus

Frankgasse 8, 1090 Vienna, Austria

The Billrothhaus (Frankgasse 8, 1090 Vienna) is located in the centre of Vienna, close to the University of Vienna's old AKH [General Hospital] campus and the Austrian National Bank. There are good public transport connections, and the Billrothhaus is within easy reach from the following stations: Schottentor (metro U2, tram lines 1, 37, 38, 40, 41, 42, 43, 44, 71, D), Landesgerichtsstrasse (tram lines 43, 44), Schwarzschanerstrasse (tram lines 37, 38, 40, 41, 42) and Lange Gasse (tram lines 5, 33).

If arriving by car, there are short-stay parking zones near the Billrothhaus (Mon-Fri 9 a.m. to 10 p.m.; max. stay 2 hours). There is also underground parking nearby Otto Wagnerplatz (more detailed information available at www.bestinparking.at) and at Votivpark (www.wipark.at, website in German only).

Starting in 2026, the Billrothhaus will have direct metro access with the U5 line which is currently being constructed. We recommend using public transportation whenever possible. The extensive construction site and diversions also impact the parking situation (no short-term parking zone directly in front of the Billrothhaus).

Vienna

For information about Vienna, visit the official Vienna info website: www.wien.info

For information about public transportation in Vienna, visit the website of the Wiener Linien: www.wienerlinien.at

The NMN acknowledges and is grateful for the support of the Vienna Tourist Board.

MEETING
DESTINATION
VIENNA
NOW ♦ TOGETHER

Cloakroom/Luggage compartment

Cloakroom and luggage compartment will be available but unattended; no liability will be assumed. You can find both on the first floor (see page 21).

Opening hours:

Friday, April 26, 2024: 08:30 – 18:00 hrs

Saturday, April 27, 2024: 08:30 – 17:00 hrs

Social Media

Stay connected!

Follow us on LinkedIn and X and subscribe to our newsletter for updates and news.


Join the conversation! Use the hashtag #NMN2024 for your posts.



*Nuclear Medicine and
Neurooncology (NMN)*



@NMNSymposium



Sign up for news

WIFI

Network: bhwireless

Password: bill22bill333

Conference Policy

Badges

Permission to the symposium (scientific sessions, exhibition and poster area) is only permitted to registered participants. Therefore, wearing your badge throughout the entire symposium is mandatory!

Language

The official language is English (no simultaneous translation available).

Certificate of attendance

Confirmations of attendance will be issued via email to all participants after the symposium.

GENERAL INFORMATION

Catering

During the lunch breaks, a light lunch as well as coffee and tea will be offered free of charge to participants wearing name badges in the exhibition area.

During the afternoon coffee breaks, refreshments (coffee, tea and snacks) will be served free of charge to participants wearing name badges in the exhibition area.

Additionally, water will be provided for free and coffee will be provided during the day in the exhibition area.

Smoking policy

The NMN 2024 Symposium is officially a “no-smoking-congress”. Note that smoking is banned in public buildings and private businesses in Vienna (e.g. restaurants, shops, public transport, entertainment venues and workplaces).

Sustainability

The NMN is committed to environmental sustainability, a responsible use of resources and sustainable congress materials. The organizer therefore asks you to keep these aspects in mind, e.g. by using public transport to get to the venue and networking event.

NETWORKING EVENT

Please note that the number of participants for the networking event is limited and advance registration is mandatory for the event. Admission will only be granted with a valid ticket. Check ticket availability at the registration desk.


- Location:** Wappensaalgruppe at the Vienna City Hall
Lichtenfelsgasse 2/Feststiege 2, 1010 Vienna
- Public transport:** Tramway 1/71/D/U2Z Station “Rathausplatz, Burgtheater”
- Date:** Friday, April 26, 2024
- Time:** 19:00 – 23:00 hrs, admission from 18:30 hrs

Individual arrival. Dresscode: casual

Spend a nice evening with your colleagues while enjoying dinner and drinks in the city hall of Vienna.


The City of Vienna and the Mayor Dr. Michael Ludwig are hosting this evening.





Scientific Chair:
Nathalie Albert, Munich

Scientific Co-Chair:
Matthias Preusser, Vienna



SAVE
THE
DATE

NMN Symposium

09.-10. May 2025
Vienna, Austria


www.nmn-society.org

Nuclear Medicine and Neurooncology (NMN)

FLOOR PLAN


Ground Floor





FLOOR PLAN

2nd Floor





ONCOLOGY

FROM THE PERSPECTIVE OF LIFE

Aranesp®
(Darbepoetin alfa)

 **BLINCYTO®**
(blinatumomab)


IMLYGIC®
talimogene laherparepvec
INTRALESIONAL INJECTION

 **KANJINTI®**
(trastuzumab)

Kyprolis®
(carfilzomib) Powder
for solution
for infusion


LUMYKRAS®
(Sotorasib)

 **MVASI®**
(Bevacizumab)

 **Neulasta®**
(Pegfilgrastim)

 **Nplate®**
Romiplostim

Von Anfang an – 100% human
Vectibix®
Panitumumab

XGEVA®
(denosumab)



Advanced
Accelerator
Applications

A Novartis Company



ADVANCED ACCELERATOR APPLICATIONS – IHR PARTNER IN DER NUKLEARMEDIZIN



Wir beliefern Sie
zuverlässig mit
hochwertigen
PET-Tracern.



Dank stabiler
Lieferkette und zu-
verlässigem Back-
up-System sorgen
wir für **pünktliche
Lieferungen** Ihrer
benötigten PET-*in-
vivo*-Diagnostika.



Unsere Produkte
und unser Kunden-
service erfüllen
**höchste Quali-
tätsansprüche**
gemäß GMP- und
GDP-Standards für
präzise Diagnosen
mit Rund-um-die-
Uhr-Erreichbarkeit.



www.adacap.com/de

VERLÄSSLICH IN PRODUKTION UND SERVICE

Advanced Accelerator Applications Germany GmbH
Saime-Genc-Ring 18, 53121 Bonn

AAA-CORP-DE-0055-v01

Reimagining Nuclear Medicine

Transforming patients' lives by leading innovation

Novartis is reimagining medicine to improve and extend people's lives.

We deliver high-value medicines that alleviate society's greatest disease burdens through **technology leadership in R&D** and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development.

About **108,000 people** of more than **140 nationalities** work together to bring Novartis products to nearly **800 million people** around the world.



Rich Oncology Pipeline

Targeting multiple
tumor types



Reimagining

Nuclear medicine by
developing drugs for targeted
radioligand therapy and
precision radioligand imaging

 NOVARTIS